Response to Bell: industry perspective

Diabetes Care. 2001 Apr;24(4):769-70. doi: 10.2337/diacare.24.4.769.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Bioethics*
  • Clinical Trials as Topic / standards*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Drug Industry*
  • Ethics, Medical*
  • Humans
  • Hypoglycemic Agents / therapeutic use*

Substances

  • Hypoglycemic Agents